Case Study

Cyna Pharma: Reaping the rewards of perseverance (B)

5 pages
January 2022
Reference: IMD-7-2317

The B case describes the events – including the offers and the negotiation – leading up to Sundown’s acquisition of Cyna for US$40.50 per share in cash or US$624 million (approximately C$841 million) – a 120% premium over the closing price of just over US$18 a share before the deal was announced. The case also brings the reader up to date on the turns Anthony’s life has taken since the acquisition and some of the exciting ventures in which he is now involved.

Learning Objective
  • Managing growth in a biopharma company
  • Leadership in a pharma company, from start-up to listed firm and trade sale
  • Developing resilience in a firm – managing risk
Keywords
Biopharmaceutical, Initial Public Offering, Clinical Trial, Funding, Acquisition
Settings
Canada
Cyna Pharma (Disguised), Healthcare, Biopharmaceuticals
2002–2016
Type
Field Research
Copyright
© 2022
Available Languages
English
Case clearing houses
Contact

Research Information & Knowledge Hub for additional information on IMD publications

This case study is part of a series
  • Cyna Pharma: Reaping the rewards of perseverance (A)
  • Cyna Pharma: Reaping the rewards of perseverance (B)
This case study is part of a series
  • Cyna Pharma: Reaping the rewards of perseverance (A)
  • Cyna Pharma: Reaping the rewards of perseverance (B)
Discover our latest research
IMD's faculty and research teams publish articles, case studies, books and reports on a wide range of topics
Cyna Pharma: Reaping the rewards of perseverance (A)
By Benoit F. Leleux Jennifer Jordan Omar Toulan and Beverley Lennox
Case reference: IMD-7-2316 ©2022
Summary
The A case tells the story of Anthony Giovinazzo’s entrepreneurial journey with Cyna Pharma, which he built from the ground up. Cyna Pharma was a C...
Reference IMD-7-2316
Copyright ©2022
Copyright owner IMD Copyright
Organization Cyna Pharma (Disguised)
Industry Healthcare, Biopharmaceuticals
Available Languages English
Contact

Research Information & Knowledge Hub for additional information on IMD publications

Cyna Pharma: Reaping the rewards of perseverance (B)
By Benoit F. Leleux Jennifer Jordan Omar Toulan and Beverley Lennox
Case reference: IMD-7-2317 ©2022
Summary
The B case describes the events – including the offers and the negotiation – leading up to Sundown’s acquisition of Cyna for US$40.50 per share in ...
Reference IMD-7-2317
Copyright ©2022
Copyright owner IMD Copyright
Organization Cyna Pharma (Disguised)
Industry Healthcare, Biopharmaceuticals
Available Languages English
Contact

Research Information & Knowledge Hub for additional information on IMD publications